Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 187


Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.

Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clément JF, Wang X, Bagul M, Gee M, Zhu J, Squillacote D.

Epilepsia. 2014 Jul;55(7):1058-68. doi: 10.1111/epi.12643. Epub 2014 May 27.


Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.

Montouris G, Yang H, Williams B, Zhou S, Laurenza A, Fain R.

Epilepsy Res. 2015 Aug;114:131-40. doi: 10.1016/j.eplepsyres.2015.04.011. Epub 2015 May 1.


Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.

Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, Yang H, Gee M, Zhu J, Laurenza A.

Epilepsia. 2013 Jan;54(1):126-34. doi: 10.1111/j.1528-1167.2012.03648.x. Epub 2012 Aug 20.


Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.

French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, Laurenza A.

Epilepsia. 2013 Jan;54(1):117-25. doi: 10.1111/j.1528-1167.2012.03638.x. Epub 2012 Aug 20.


Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.

Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, Squillacote D, Yang H, Zhu J, Laurenza A.

Epilepsia. 2013 Aug;54(8):1481-9. doi: 10.1111/epi.12212. Epub 2013 May 10.


Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.

Gidal BE, Ferry J, Majid O, Hussein Z.

Epilepsia. 2013 Aug;54(8):1490-7. doi: 10.1111/epi.12240. Epub 2013 Jun 17.


Perampanel: expanding therapeutic options for patients with medically refractory secondary generalized convulsive seizures.

Ko D, Ramsay RE.

Acta Neurol Scand Suppl. 2013;(197):36-43. doi: 10.1111/ane.12103. Review.


Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.

Rosenfeld W, Conry J, Lagae L, Rozentals G, Yang H, Fain R, Williams B, Kumar D, Zhu J, Laurenza A.

Eur J Paediatr Neurol. 2015 Jul;19(4):435-45. doi: 10.1016/j.ejpn.2015.02.008. Epub 2015 Mar 5.


Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial.

Kwan P, Trinka E, Van Paesschen W, Rektor I, Johnson ME, Lu S.

Epilepsia. 2014 Jan;55(1):38-46. doi: 10.1111/epi.12391. Epub 2013 Oct 3.


Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304.

French JA, Krauss GL, Biton V, Squillacote D, Yang H, Laurenza A, Kumar D, Rogawski MA.

Neurology. 2012 Aug 7;79(6):589-96. doi: 10.1212/WNL.0b013e3182635735. Epub 2012 Jul 25.


Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.

Strzelczyk A, Willems LM, Willig S, Rosenow F, Bauer S.

Expert Rev Clin Pharmacol. 2015;8(6):733-40. doi: 10.1586/17512433.2015.1091303. Epub 2015 Oct 5. Review.


Adjunctive perampanel in adolescents with inadequately controlled partial-onset seizures: A randomized study evaluating behavior, efficacy, and safety.

Lagae L, Villanueva V, Meador KJ, Bagul M, Laurenza A, Kumar D, Yang H.

Epilepsia. 2016 Jul;57(7):1120-9. doi: 10.1111/epi.13417. Epub 2016 May 25.


Perampanel: as adjunctive therapy in patients with partial-onset seizures.

Plosker GL.

CNS Drugs. 2012 Dec;26(12):1085-96. doi: 10.1007/s40263-012-0021-2. Review.


Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial.

Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S.

Epilepsia. 2014 Jan;55(1):57-66. doi: 10.1111/epi.12433. Epub 2013 Nov 8.


Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.

French JA, Krauss GL, Wechsler RT, Wang XF, DiVentura B, Brandt C, Trinka E, O'Brien TJ, Laurenza A, Patten A, Bibbiani F.

Neurology. 2015 Sep 15;85(11):950-7.


Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies.

Kramer LD, Satlin A, Krauss GL, French J, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Laurenza A, Yang H, Zhu J, Squillacote D.

Epilepsia. 2014 Mar;55(3):423-31. doi: 10.1111/epi.12527. Epub 2014 Mar 7.


Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures.

Krauss GL, Serratosa JM, Villanueva V, Endziniene M, Hong Z, French J, Yang H, Squillacote D, Edwards HB, Zhu J, Laurenza A.

Neurology. 2012 May 1;78(18):1408-15. doi: 10.1212/WNL.0b013e318254473a. Epub 2012 Apr 18.


Perampanel Study 207: long-term open-label evaluation in patients with epilepsy.

Rektor I, Krauss GL, Bar M, Biton V, Klapper JA, Vaiciene-Magistris N, Kuba R, Squillacote D, Gee M, Kumar D.

Acta Neurol Scand. 2012 Oct;126(4):263-9. doi: 10.1111/ane.12001. Epub 2012 Aug 23.


Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial.

Husain A, Chung S, Faught E, Isojarvi J, McShea C, Doty P.

Epilepsia. 2012 Mar;53(3):521-8. doi: 10.1111/j.1528-1167.2012.03407.x.

Supplemental Content

Support Center